Clinical trials: Non Organic Psychosis
Schizophreniform Disorders, Bipolar Disorder
REWRITALIZE Your Recovery - Evaluation of a Creative Writing Group Intervention
Health institutes call for psychosocial interventions and recovery-oriented approaches as supplement to pharmacological treatment for mental health disorders.
- Conditions
- Schizophreniform Disorders, Bipolar Disorder, Severe Depression, Ptsd
- Trial name
- REWR (NCT06251908)
- Testing
- Rewritalize, Standard mental health care
- Where
- 6 sites in Denmark
- Volunteers
- 300 people
- Sponsor
- Amager Hospital
Delusional Disorder, Brief Psychotic Disorder
FEEL-GOOD: A Multicenter Trial of a Mindfulness-Based Group Therapy in Young Adults With Early Psychosis
FEEL-GOOD is a prospective multi-site single-blinded randomized controlled trial in young inpatients with acute early psychosis. Participants are randomized 1:1 to FEEL-GOOD plus treatment as usual (TAU) or TAU alone.
- Conditions
- Delusional Disorder, Brief Psychotic Disorder, Schizophreniform Disorder, Schizophrenia / Schizoaffective Disorder
- Trial name
- FEEL-GOOD (NCT07645443)
- Testing
- FEEL GOOD, Treatment as Usual (TAU)
- Where
- 8 sites in Germany
- Volunteers
- 252 people
- Sponsor
- Stephanie Mehl
Schizophrenia, Schizoaffective Disorder
Shared Decision Making for Antipsychotic Medications
This study aims to provide an evidence-based shared decision making intervention for antipsychotic medications, the Antipsychotic Medication Decision Aid (APM-DA), for individuals experiencing early psychosis and provide, for the…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorders, Delusional Disorder
- Trial name
- NCT05416658
- Testing
- The Antipsychotic Medication Decision Aid (APM-DA)
- Volunteers
- 120 people
- Sponsor
- New York State Psychiatric Institute
Clinical High Risk Syndrome of Psychosis
Decreasing Risk of Psychosis by Sulforaphane (DROPS Trial)
This is a randomized, double-blind, placebo-controlled, multi-centre trial. A total of 300 CHR subjects will be identified in the course of face-to-face interviews using the Structured Interview for Prodromal Syndromes.
- Trial name
- NCT03932136
- Testing
- Sulforaphane
- Where
- 9 sites in China
- Volunteers
- 300 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Schizophrenia, Cognition
Curcumin as a Novel Treatment to Improve Cognitive Dysfunction in Schizophrenia
The investigators propose to test whether curcumin nanoparticles will improve behavioral measures and biomarkers of cognition and neuroplasticity in patients with schizophrenia who are already receiving a stable dose of…
- Conditions
- Schizophrenia, Cognition, Psychosis
- Trial name
- NCT02104752
- Testing
- Curcumin
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- VA Greater Los Angeles Healthcare System
Psychosis Associated With Alzheimer's Disease
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)
This is a Phase 3, 38-week, randomized, double-blind, placebo-controlled, multicenter, outpatient study in subjects with psychosis associated with Alzheimer's Disease.
- Trial name
- NCT05511363
- Testing
- KarXT
- Where
- 129 sites in United States, Bulgaria and 11 more
- Volunteers
- 410 people
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Psychotic Disorder, Schizoaffecitve Disorder
Glycine to Treat Psychotic Disorders in Children
This study will test the safety and effectiveness of the amino acid glycine in treating psychotic disorders in children. The drug will be given as an adjunct (in addition) to the patient's current antipsychotic medication.
- Conditions
- Psychotic Disorder, Schizoaffecitve Disorder, Schizophrenia
- Trial name
- NCT00005658
- Testing
- Glycine
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Institute of Mental Health (NIMH)
Psychotic Disorders, Psychosis
Pilot Study of Motivational Interviewing for Loved Ones
The study population for this research will include parents and concerned significant others (PCSO) of individuals experiencing recent (past five years) onset of a psychotic disorder (hereafter referred to as individuals with…
- Conditions
- Psychotic Disorders, Psychosis, Psychotic Episode
- Trial name
- MILO-Pilot (NCT04010747)
- Testing
- Motivational Interviewing for Loved Ones (MILO), Mental Health Services Consultation and Waitlist
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- Boston Medical Center
Psychosis, Intellectual Disability
Study to Compare Clozapine vs Treatment as Usual in People With Intellectual Disability & Treatment-resistant Psychosis
This clinical trial will prove whether a large number of people with intellectual disability and treatment-resistant psychosis could benefit from the use of clozapine.
- Trial name
- CLOZ-AID (NCT04529226)
- Testing
- Clozapine, haloperidol, pimozide, olanzapine, risperidone, amisulpride
- Where
- 20 sites in Spain
- Volunteers
- 75 people
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Family Members, Implementation
FAmily Engagement Strategy for Coordinated Specialty Care
Family members/support persons' engagement in mental health services has been linked to reduced burden and stress and improves engagement and outcomes in individuals in the early stages of psychosis.
- Trial name
- FAMES (NCT06945055)
- Testing
- FAMES, Control
- Where
- 4 sites in United States
- Volunteers
- 900 people
- Sponsor
- Washington State University
First Episode Psychosis (FEP), Caregiver Burden
Psychoeducation Program for Family Caregivers Coordinated by an APRN
The aim of this study is to assess the impact of implementing a specific family program coordinated by APRNs, covering the 5 levels of the family care pyramid through a consultation, an individual psychoeducation program and a…
- Conditions
- First Episode Psychosis (FEP), Caregiver Burden, Nurse Practitioners, IMPACT OF A NEW PSYCHOEDUCATION PROGRAM COORDINATED BY AN ADVANCED PRACTICE NURSE ON THE BURDEN OF FAMILY CAREGIVERS OF PATIENTS WITH A FIRST PSYCHOTIC EPISODE
- Trial name
- APIPEP (NCT07041463)
- Testing
- Psychoeducation program coordinated by an APRN, Usual Care
- Where
- 5 sites in France
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Hôpital le Vinatier
Healthy Volunteers, Modeling Psychosis
Gene-Environment-Interaction: Influence of the COMT Genotype on the Effects of Different Cannabinoids - a PET Study
The study evaluates the gene-environment interaction of the COMT-genotype on the effects of the phytocannabinoids delta-9-tetrahydrocannabinol, cannabidiol or a combination of both on induction of psychotic symptoms…
- Trial name
- NCT02492074
- Testing
- Delta-9-tetrahydrocannabinol, Cannabidiol
- Where
- Germany
- Volunteers
- healthy volunteers welcome
- Sponsor
- Central Institute of Mental Health, Mannheim
First Episode Psychosis
Socially Inappropriate Behaviour in People With First Episode Psychosis: A Caregivers' Perspective
Social impairment is one of the core symptoms in first episode psychosis (FEP). Despite negative symptoms and social cognition impairment found in patient suffering from FEP, clinicians occasionally identified socially…
- Trial name
- NCT03501160
- Testing
- Face-to face semi-structured in-depth interview
- Where
- 2 sites in Hong Kong
- Volunteers
- 8 people
- Sponsor
- Chinese University of Hong Kong
Psychosis, Mental Disorder
Assessment and Evolution of Narrative Identity and Its Relationship to Subjective Multidimensional Well-being and Multidimensional Recovery in First Episode Psychosis
First episode psychosis (FEP) constitutes an important subgroup within psychotic disorders, as the acute impact of a disorder at the time of diagnosis may differ from its long-term impact over the following decades.
- Trial name
- PEPID (NCT07330843)
- Testing
- Narrative identity task
- Where
- France
- Volunteers
- 96 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Psychiatric or Mood Diseases or Conditions, Neuropsychiatric Syndrome
Effect and Cost-effectiveness of the Everyday Life Rehabilitation Intervention
The person-centered, motivational, recovery-, and activity-based intervention model 'Everyday Life Rehabilitation´ (ELR), integrated in sheltered and supported housing facilities for people with severe psychiatric disabilities…
- Conditions
- Psychiatric or Mood Diseases or Conditions, Neuropsychiatric Syndrome, Psychosis, Autism
- Trial name
- ELR (NCT05056415)
- Testing
- Everyday Life Rehabilitation (ELR), Treatment as usual (TAU)
- Where
- Sweden
- Volunteers
- 161 people
- Sponsor
- Umeå University
Schizophrenia
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia
ML-007C-MA-211 is a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of orally administered ML-007C-MA in inpatient adult participants aged 18 to 64 years with…
- Trial name
- NCT07038876
- Testing
- ML-007C-MA BID, ML-007C-MA QD
- Where
- 24 sites in United States
- Volunteers
- 307 people
- Sponsor
- MapLight Therapeutics
Clinical High Risk for Psychosis
tDCS Coupled With Virtual Rehabilitation for Negative Symptoms in At-Risk Youth
Negative symptoms, which include the loss of motivation, social withdrawal and reduced emotional expression are prominent in youth at clinical high risk (CHR) for psychosis.
- Trial name
- NCT02951208
- Testing
- Active tDCS, Active VR Motivation Training
- Where
- Canada
- Volunteers
- 22 people
- Sponsor
- Centre for Addiction and Mental Health
Psychotic Disorders, Veterans
Impact of VVV Group for Veterans With SMI
Veterans with Serious Mental Illness (SMI) struggle with social integration - participation in work, housing, and citizenship - due to symptoms, stigma, and psychosocial challenges.
- Trial name
- VVV (NCT05562674)
- Testing
- Veteran Voices and Visions
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- VA Office of Research and Development
Schizophrenia, Schizoaffective Disorder
Second-Generation Antipsychotic Treatment Indication Effectiveness And Tolerability In Youth (Satiety) Study
The purpose of this study is to get a better understanding of the side effect burden and identify predictors of psychotic, mood and aggressive disorders in children and adolescents.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychotic Disorder, Not Otherwise Specified
- Trial name
- SATIETY (NCT01269710)
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of North Carolina, Chapel Hill
Dementia, Alzheimer Disease
Efficacy and Safety of Risperidone Compared With Placebo in the Treatment of Psychotic Symptoms in Patients With Alzheimer's Disease
The purpose of this study is to evaluate the efficacy and safety of risperidone compared with placebo in the treatment of psychotic symptoms in patients with Alzheimer's disease
- Conditions
- Dementia, Alzheimer Disease, Mental Disorders
- Trial name
- NCT00034762
- Testing
- risperidone
- Volunteers
- 473 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.